Highlights

  • LTR Pharma develops intranasal drug delivery products for erectile dysfunction.
  • The final Phase II SPONTAN report found median peak drug concentration at 10 minutes, compared with 60 minutes for oral vardenafil.
  • The company reported no serious adverse events or treatment discontinuations in its pharmacokinetic study.
  • LTR Pharma confirmed the first US ROXUS patient-specific prescriptions had been fulfilled on 6 October 2026.
  • The SPONTAN regulatory programme includes work supporting a planned US 505(b)(2) application.

LTR Pharma Limited (ASX:LTP) is an Australian pharmaceutical company developing and commercialising intranasal treatments for erectile dysfunction. Its products include SPONTAN, an investigational nasal formulation of the PDE5 inhibitor vardenafil, and ROXUS, a related intranasal offering. During 2026, the company reported results from SPONTAN clinical pharmacokinetic testing and disclosed the beginning of prescription fulfilment for ROXUS in the United States.

What the Phase II Study Established

On 1 October 2026, LTR Pharma Limited (ASX:LTP) reported receipt of the final Clinical Study Report for its Phase II SPONTAN pharmacokinetic study. The report confirmed a median time to peak concentration of 10 minutes following intranasal administration, compared with 60 minutes for oral vardenafil tablets. The company described the difference as six-fold faster absorption and reported a statistical result of p<0.0001. These are pharmacokinetic measurements rather than proof that every patient will experience a clinical effect within 10 minutes.

The company also reported that a 5 mg SPONTAN dose produced approximately one-quarter of the total drug exposure of a 20 mg oral tablet. Five days of once-daily administration did not produce drug accumulation in the study, while pharmacokinetic results were comparable for participants aged 65 and above. LTR Pharma Limited (ASX:LTP) stated that no serious adverse events, Grade 3 or higher events, or treatment discontinuations occurred.

Why the Nasal Route Matters

The nasal lining contains blood vessels that can facilitate absorption through mucosal tissue. Unlike a swallowed tablet, an intranasal formulation may avoid gastrointestinal absorption and some first-pass metabolism in the liver. LTR Pharma Limited (ASX:LTP) is applying this route to vardenafil, aiming to change the timing and amount of drug exposure while preserving its intended therapeutic role. The company’s reported Phase II findings provide measured evidence about absorption; efficacy, tolerability and labelling remain subjects of clinical and regulatory assessment.

US ROXUS Activity and Regulatory Work

On 6 October 2026, the company confirmed that the first patient-specific ROXUS prescriptions through a US telehealth distribution arrangement had been fulfilled. This establishes an initial fulfilment milestone, although LTR Pharma Limited (ASX:LTP) did not disclose prescription volume, revenue or profitability in that update. ROXUS commercial activity is distinct from the regulatory development programme for SPONTAN, and the two should not be treated as equivalent forms of authorisation.

The Phase II final report completes the pharmacokinetic dataset agreed for the company’s planned US 505(b)(2) submission. LTR Pharma Limited (ASX:LTP) said the programme was moving into submission-enabling activities in the second half of calendar 2026. Completion of a dataset is not the same as filing or receiving approval.

Key Operational Considerations

A nasal medicine requires consistent dosing, reliable delivery-device performance and appropriate storage stability. The ability to reproduce pharmacokinetic findings beyond a controlled study also matters. For LTR Pharma Limited (ASX:LTP), implementation depends on manufacturing and distribution arrangements, evidence accepted by regulators, and the terms under which patients can obtain each product. Its October disclosures document progress on both clinical data and initial US fulfilment, but they do not establish the longer-term commercial scale of either product.

Key Insights

LTR Pharma’s 2026 updates distinguish three stages: measured drug absorption in a clinical study, preparatory work for an intended SPONTAN regulatory submission, and initial ROXUS prescription fulfilment in the United States. Each represents a different type of evidence. The disclosed results support a description of the technology’s pharmacokinetic characteristics without establishing future approval decisions, widespread patient outcomes or commercial revenues.